Bespoke Extracts (BSPK) Amortizatization of Intangibles (2011 - 2025)
Bespoke Extracts (BSPK) reported Amortizatization of Intangibles of $22134.0 for Q3 2025, up 768.0% on a YoY basis from $2550.0 in Q3 2024, and up 90.35% sequentially from $11628.0 in Q2 2025.
Bespoke Extracts (BSPK) Amortizatization of Intangibles (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 10 years of Amortizatization of Intangibles data on file, last reported at $22134.0 in Q3 2025.
- For the quarter ending Q3 2025, Amortizatization of Intangibles rose 768.0% year-over-year to $22134.0; the trailing twelve-month figure through Sep 2025 stood at $48365.0 (up 116.9% YoY), and the FY2024 full-year result was $9335.0, changed N/A from the prior year.
- Amortizatization of Intangibles rose to $22134.0 in Q3 2025, from $11628.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $22134.0 in Q3 2025 to a low of $942.0 in Q1 2024.
- A 4-year average of $11263.2 and a median of $13686.5 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles sank 94.24% in 2024 and jumped 1056.37% in 2025, its largest moves.
- Tracing BSPK's Amortizatization of Intangibles over 4 years: stood at $15893.0 in 2022, then climbed by 4.91% to $16673.0 in 2023, then plunged by 77.75% to $3710.0 in 2024, then surged by 496.6% to $22134.0 in 2025.
- Business Quant data shows BSPK's Amortizatization of Intangibles at $22134.0 in Q3 2025, $11628.0 in Q2 2025, and $10893.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 22,134.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 22,134.00 |
| Sep 30, 2025 | 22,134.00 |
| Jun 30, 2025 | 11,628.00 |
| Jun 30, 2025 | 11,628.00 |
| Mar 31, 2025 | 10,893.00 |
| Mar 31, 2025 | 10,893.00 |
| Dec 31, 2024 | 3,710.00 |
| Dec 31, 2024 | 3,710.00 |
| Sep 30, 2024 | 2,550.00 |
| Sep 30, 2024 | 2,550.00 |
| Jun 30, 2024 | 2,133.00 |
| Jun 30, 2024 | 2,133.00 |
| Mar 31, 2024 | 942.00 |
| Mar 31, 2024 | 942.00 |
| Sep 30, 2023 | 16,673.00 |
| Sep 30, 2023 | 16,673.00 |
| Jun 30, 2023 | 16,510.00 |
| Jun 30, 2023 | 16,510.00 |
| Mar 31, 2023 | 16,348.00 |
| Mar 31, 2023 | 16,348.00 |